Results 31 to 40 of about 63,717 (177)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis

open access: yesHaematologica, 2018
Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib.
Mathias Schneeweiss   +19 more
doaj   +1 more source

Mast Cell Sarcoma of the Retroperitoneum With Concurrent Systemic Mastocytosis and an Undisclosed Associated Hematologic Neoplasm: A Case Report

open access: yesClinical Pathology, 2022
Mastocytosis is a rare disorder affecting both children and adults by gathering of functionally defective mast cells in the body’s tissues. The World Health Organization (WHO) classified mastocytosis into cutaneous mastocytosis, systemic mastocytosis (SM)
Ing Chen   +4 more
doaj   +1 more source

Diffuse large B cell lymphoma coexistence with systemic mastocytosis

open access: yesJournal of Cancer Research and Practice, 2016
Systemic mastocytosis is a rare disease and characterized by excessive mast cell accumulation in one or multiple organs. One subtype of systemic mastocytosis is systemic mastocytosis-associated clonal hematological non-mast cell lineage disease (SM-AHMND)
Sheng-Hsuan Chien   +8 more
doaj   +1 more source

Solitary mastocytoma presenting in an adult: report and literature review of adult-onset solitary cutaneous mastocytoma with recommendations for evaluation and treatment

open access: yesDermatology Practical & Conceptual, 2016
Background: Mastocytosis is either cutaneous (with skin-limited proliferation of mast cells) or systemic (with mast cells in extracutaneous sites). The onset of solitary mastocytoma in an adult is rare.
Philip R. Cohen
doaj   +1 more source

CD30 in Systemic Mastocytosis

open access: yesImmunology and Allergy Clinics of North America, 2014
CD30 is a transmembrane receptor, normally not expressed by mast cells, which regulates proliferation/apoptosis and antibody responses. Aberrant expression of CD30 by mastocytosis mast cells and interaction with its ligand CD30L (CD153) appears to play an important role in the pathogenesis and clinical presentation of systemic mastocytosis.
van Anrooij, Bjorn   +3 more
openaire   +2 more sources

An intriguing coexistence of cutaneous and systemic mastocytosis with atypical chronic myeloid leukemia: An associated hematologic neoplasm (SM-AHN)

open access: yesJournal of Applied Hematology, 2021
Systemic mastocytosis (SM) characterized by focal or diffuse infiltrates of neoplastic mast cells can range from indolent cutaneous disease to aggressive systemic disease.
B R Rajalakshmi, Vijaya Basavaraj
doaj   +1 more source

Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean   +2 more
wiley   +1 more source

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

open access: yesAllergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy   +7 more
wiley   +1 more source

Gastrointestinal tract involvement in systemic mastocytosis: a clinical case

open access: yesPatologìâ
Mastocytosis is a group of rare heterogeneous diseases caused by excessive proliferation and accumulation of mast cells in various organs and systems.
Ya. S. Bereznytskyi   +5 more
doaj   +1 more source

Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab

open access: yesCase Reports in Medicine, 2015
The pathogenesis of mastocytosis is not well defined and thus treatment remains challenging and remains on a palliative basis. We present two cases (a 48-year-old woman and a 57-year-old man) with indolent systemic mastocytosis in whom omalizumab (anti ...
Sofie Lieberoth, Simon Francis Thomsen
doaj   +1 more source

Home - About - Disclaimer - Privacy